Key Takeaways
- Eli Lilly’s experimental medication retatrutide enabled participants to shed up to 70.3 pounds (28.3% body weight reduction) during an 80-week Phase 3 study.
- Data suggests superior performance versus Lilly’s existing obesity treatments Zepbound and Foundayo when comparing trial outcomes.
- Approximately 45% of 2,500 study participants reached 30% or greater weight reduction — a benchmark historically linked only to surgical intervention.
- A reduced 4mg dosage demonstrated excellent tolerance, with discontinuation rates lower than the placebo cohort.
- LLY shares increased roughly 1% Thursday morning; year-to-date, the stock remains down approximately 5%.
Eli Lilly’s upcoming obesity medication has delivered some of the most remarkable efficacy data witnessed in weight management therapy.
Retatrutide, administered as a once-weekly injection targeting three digestive hormones, successfully completed a pivotal late-stage clinical study Thursday. Participants with obesity receiving the maximum 12mg dosage achieved an average 28.3% body weight reduction — approximately 70.3 pounds — across 80 weeks. The 9mg dosage group lost an average of 64.4 pounds.
The control group receiving placebo treatment, in comparison, experienced only 2.2% body weight reduction.
LLY stock traded approximately 1% higher during Thursday’s morning session. Year-to-date, shares have declined roughly 5.2% amid growing competition within the GLP-1 therapeutic category.
Approximately 45% of the nearly 2,500 participants enrolled in the Phase 3 study achieved 30% or greater total weight reduction. This milestone has traditionally only been attainable through surgical weight-loss procedures.
Dan Skovronsky, Lilly’s chief scientific and product officer, told CNBC that 30% weight loss is “an incredible number to see” with this class of medicine.
Retatrutide’s Performance Against Current Treatments
Retatrutide functions through a distinct mechanism compared to Lilly’s existing portfolio. It stimulates receptors for three hormones — GLP-1, GIP, and glucagon — versus two for Zepbound and a single hormone for earlier GLP-1 medications.
Though head-to-head comparisons between separate trials present challenges, the data is striking. Zepbound’s maximum dosage delivered approximately 20–22% weight reduction in its registration study. Foundayo, Lilly’s oral GLP-1 formulation, showed even more modest results.
A novel 4mg dose evaluated in this study also caught analysts’ attention. It yielded 19% weight reduction — comparable to high-dose Zepbound — while demonstrating superior tolerability. Only 4% of participants receiving this dose discontinued due to adverse reactions, versus nearly 5% in the control arm.
The medication’s safety characteristics aligned broadly with other GLP-1 therapies. Digestive system reactions including nausea (42% at maximum dose) and diarrhea (32%) were most frequently reported. No cardiovascular or hepatic complications emerged, addressing concerns some analysts had raised regarding the drug’s glucagon activity.
Lilly noted a moderately elevated urinary tract infection rate compared to placebo, though most cases were mild. Skovronsky indicated the UTIs might correlate with the rapid and substantial weight reduction, noting comparable patterns following surgical weight-loss procedures.
Retatrutide’s Regulatory Pathway Forward
This marks the third successful late-stage outcome for retatrutide. The drug previously succeeded in a diabetes study earlier this year and passed a smaller trial involving patients with obesity and knee osteoarthritis in December 2025.
TD Cowen analysts project the medication could reach $3.8 billion in annual revenue by 2030, contingent on approval.
Lilly commands approximately 60% of the GLP-1 market share, according to company data. Novo Nordisk’s Wegovy pill has captured market share in the oral weight-loss category, where Lilly’s Foundayo also operates.
Lilly announced it will leverage these findings to advance toward regulatory submission for retatrutide.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
